On December 18, 2025, President Donald J. Trump signed an Executive Order directing the Attorney General to finalize the rulemaking that would move marijuana from Schedule I to Schedule III of the Controlled Substances Act - and to do it fast. For state-legal cannabis operators and the CPAs who serve them, that directive carries a specific and consequential implication: the potential end of IRC Section 280E, the tax code provision that has functioned, for decades, as a slow financial hemorrhage for an otherwise legitimate industry.
What the Order Actually Says - and Why the Language Matters
The Executive Order, titled "Increasing Medical Marijuana and Cannabidiol Research," covers several areas including hemp-derived products and research infrastructure. But the operative language for tax professionals sits in Section 2(a), which instructs the Attorney General to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner in accordance with Federal law."
That phrase - "most expeditious manner" - is doing real work here. The rulemaking itself is not new. The Department of Justice and the Drug Enforcement Administration issued a Notice of Proposed Rulemaking in May 2024, following a recommendation from the Department of Health and Human Services. HHS had determined that marijuana has a currently accepted medical use for conditions including anorexia, nausea, and pain, and that its abuse potential falls below that of Schedule I and II substances. The proposed rule drew nearly 43,000 public comments and is currently awaiting an administrative law hearing - the procedural bottleneck the Executive Order is now pressuring to resolve.
What's striking here is the political reversal embedded in this moment. The rescheduling effort began under the Biden administration. Trump's order, framed around research and medical access, effectively accelerates a process his predecessor initiated - and in doing so, may deliver one of the most consequential federal tax changes the cannabis industry has ever seen.
The 280E Problem, Plainly Stated
IRC Section 280E was enacted in the 1980s following a Tax Court decision that allowed a cocaine dealer to deduct business expenses. Congress responded bluntly: no deductions or credits for any trade or business that "consists of trafficking in controlled substances within the meaning of schedule I and II of the Controlled Substances Act" where that trafficking is prohibited by federal law.
The statute was written to target criminal enterprises. Instead, it has spent years grinding down licensed dispensaries, cultivators, and processors operating in full compliance with state law. Because marijuana remains Schedule I, these businesses cannot deduct rent, payroll, utilities, or marketing costs - expenses that every other American business treats as table stakes. They are generally limited to deducting Cost of Goods Sold. The effective federal tax rates that result can exceed 70%, an extraordinary burden that has pushed otherwise solvent operators into insolvency and made external financing structurally difficult to obtain.
The mechanism of relief is straightforward: 280E explicitly applies only to substances "within the meaning of schedule I and II." Rescheduling marijuana to Schedule III removes it from that statutory definition. The DOJ's own Regulatory Flexibility Act analysis within the 2024 NPRM acknowledges this directly, noting that if marijuana is transferred to Schedule III, "section 280E would no longer serve as a statutory bar to claiming deductions for those expenses." No legislative amendment to the tax code is required. The rescheduling itself does the work.
What Tax Professionals Should Prepare For
The finalization of the rule will not happen overnight - administrative law proceedings have their own procedural requirements that cannot simply be wished away. But the Executive Order signals that the hearing and finalization are now a priority, not a dormant item on a regulatory docket. The timeline has compressed.
Once a Final Rule is published in the Federal Register, cannabis businesses would no longer be subject to 280E and could deduct ordinary and necessary business expenses under IRC Section 162. The precise effective date - whether it applies to the full tax year in which rescheduling occurs, or only prospectively from the rule's effective date - is not yet settled. The IRS has not issued formal guidance, and the agency is expected to clarify its position once the actual rescheduling takes place. That gap matters for estimated tax payments and year-end planning.
For CPAs advising cannabis clients right now, the practical steps are clear. Monitor the Federal Register for the administrative law hearing date. Begin modeling the tax impact of restoring full Section 162 deductibility against current financial statements. Revisit estimated payment schedules, which may need to be recalibrated if rescheduling finalizes mid-year. And hold off on aggressive tax positions premised on 280E's elimination until the Final Rule is in print - the order accelerates the process; it does not replace it.
The DOJ's own analysis describes the potential economic impact on federal tax receipts as "large." That is, for once, not bureaucratic understatement.
